Trenzyme licenses 7g per litre expression tech from JRS's Celonic

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Cell line, Cell culture, Cell

Trenzyme licenses 7g/L expression tech from JRS's Celonic
Trenzyme licenses 7g/L expression tech from JRS's Celonic
Contractor Trenzyme GmbH has licensed a CHO cell line-based expression system from Swiss firm Celonic AG in a deal designed to expand its service offering.

The deal – financial terms of which were not disclosed – sees Trenzyme add Celonic’s SErum Free EXpression technology – known as SEFEX – to its tech portfolio and will allow it to provide a broader range of services according to CEO Reinhold Horlacher.

"We are very happy since the deal enables us to extend our cell line services. From now on, we can additionally offer the generation of a cell line which can not only be used for R&D but also for subsequent GMP manufacturing purposes.

Horlacher also predicted the tech would help Trenzyme’s customers – which include Roche and Actelion according to its website – save time and money.

There is no further need of two different cell lines as the generated R&D cell line can be directly upgraded to GMP manufacturing​” he said.

Biosimilar services

The licensed technology is based on Celonic’s CHO-K1 based cell line, which the Swiss firm claims can achieve antibody production titres in excess of 7g per litre.

Celonic - which has been owned by JRS Pharma since 2011 - provides contract manufacturing services to the biopharmaceutical sector.

The firm is part of the an organisation called The Biosimilar Group along with protein maker Protagen, biosimilarity specialist Nurigon, clinical services firm Assign and regulatory affairs group Pharmalex.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars